AUG 13, 2026 · PHASE 2 TRIAL
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
ClinicalTrials.gov
This is a Phase 2 trial registration with no reported results; enrollment is ongoing and efficacy data are not yet available.
Reported
Planned sample size120
PhasePHASE 2
Primary outcome measureChange in Cohen-Mansfield Agitation Invento…